Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Tottori University Hospital |
---|---|
Information provided by: | Tottori University Hospital |
ClinicalTrials.gov Identifier: | NCT00663195 |
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
Condition | Intervention | Phase |
---|---|---|
Chronic Stable Heart Failure |
Drug: spironolactone + furosemide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Efficacy Study |
Official Title: | Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure |
Enrollment: | 16 |
Study Start Date: | January 2004 |
Study Completion Date: | December 2005 |
Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.
Genders Eligible for Study: | Both |
Inclusion Criteria:
Responsible Party: | Center for Clinical Residency Program, Tottori University Hospital ( Kazuhide Ogino ) |
Study ID Numbers: | #344 |
Study First Received: | April 18, 2008 |
Last Updated: | April 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00663195 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
heart failure fibrosis MMP spironolactone furosemide |
Heart Failure Heart Diseases Fibrosis Furosemide Spironolactone |
Molecular Mechanisms of Pharmacological Action Hormone Antagonists Diuretics Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Cardiovascular Agents Pharmacologic Actions |
Membrane Transport Modulators Aldosterone Antagonists Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Sodium Potassium Chloride Symporter Inhibitors |